Figure 1 Estimated annual percentages of new

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Road to targeting mutant p53

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 Balance between proteasomal load and capacity

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 5 Palliative-care-referral patterns

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Figure 1 Estimated annual percentages of new cases of HPV-associated cancers and genital warts, by gender, in Europe Figure 1 | Estimated annual percentages of new cases of HPV-associated cancers and genital warts, by gender, in Europe1. Modified with permission from Springer Nature © Stanley M. Nature 488 (Suppl.), S10 (2012). Modified with permission from Springer Nature © Stanley M. Nature 488 (Suppl.), S10 (2012). Masterson, L. & Lechner, M. (2016) HPV vaccination in boys — will the UK join the fight? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.184